If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Eli Lilly and Company does not control, influence, or endorse this site, and the opinions, claims or comments expressed on this site should not be attributed to Eli Lilly and Company. Eli Lilly and Company is not responsible for the privacy policy of any third party web sites. We encourage you to read the privacy policy of every web site you visit.
Menu closed
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Abasaglar ® (basal insulin glargine)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Abasaglar Summary of Product Characteristics (SmPC)
Abasaglar® (insulin glargine): Use in Hepatic Impairment
The effect of hepatic impairment on the pharmacokinetics of Abasaglar has not been studied.
Detailed
Information
The
effect of hepatic impairment on the PK of Abasaglar has not been
studied.1
In
patients with hepatic impairment, insulin requirements may be
diminished due to reduced capacity for gluconeogenesis and reduced
insulin metabolism.2
As
with all insulin products, more frequent glucose monitoring and
dosage adjustment may be necessary for Abasaglar in patients with
hepatic impairment. Patients with hepatic impairment may be at higher
risk for hypoglycemia.1
Some
studies with human insulin have shown increased circulating levels of
insulin in patients with hepatic failure.1
References
1.
Data on file, Eli Lilly and Company and/or one of its subsidiaries.
2.
Abasaglar [summary of product characteristics]. Eli Lilly Nederland
B.V., The Netherlands.
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com